Sanofi has achieved genuine absolute emissions reductions (47% Scope 1&2 since 2019) and holds SBTi-validated net-zero targets, but Scope 3 progress stalls at 10% reduction. Recurring pollution incidents at Mourenx plant and mixed trade association climate positions undermine credibility. Nature outcomes remain unquantified despite frameworks.
Same formula for every company. No curve. No private weighting.
SINK = (0.3 × Base + 0.7 × Performance) × ScaleStrongest on Carbon Footprint — Operations and Targets & Commitments (8/10, 8/10). Weakest on Controversies & Red Flags and Water Impact (6/10, 6/10).
14 sources used in this assessment. All publicly available. Each row shows which rubric questions it informed.
If you believe a source has been misread or a newer version exists, submit a challenge.
Among the 11 major healthcare / pharmaceuticals brands we've scored, Sanofi sits 5th of 11.
Score history begins 4 April 2026.
As Sanofi's score updates, the trajectory will appear here.
We're backfilling historical scores for FTSE 100 and S&P 100 companies over the coming weeks.
Every challenge is published. We'd rather be corrected than wrong — that's the whole point.
No challenges submitted yet. If you have evidence that contradicts this score, you can challenge any question above — cite a public source and we'll review it.
Sanofi is a multinational pharmaceutical and healthcare company headquartered in Paris, France. It develops prescription medicines, vaccines, and consumer healthcare products across oncology, immunology, and infectious disease. A top-five global pharma player by revenue, Sanofi employs over 100,000 people across six continents.
Peer pharma giant with similar size and science-based target maturity; direct emissions performance comparison.
View breakdown →Top-five pharma competitor; enables benchmarking of Scope 3 supply chain engagement and biodiversity frameworks.
View breakdown →Largest diversified healthcare group; relevant for comparing governance integration and trade association alignment gaps.
View breakdown →Mid-cap pharma with earlier net-zero commitment; highlights Sanofi's late-mover status on 1.5°C alignment.
View breakdown →Email alerts when a rubric question is verified, a challenge is resolved, or the overall score changes.
One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.
No spam. Unsubscribe in one click.
Readers and institutions support our work. Companies can pay to submit evidence we couldn't find. Neither type of payment changes a score.